Anti-androgenic treatment of obsessive-compulsive disorder: An open-label clinical trial of the long-acting gonadotropin-releasing hormone analogue triptorelin

International Clinical Psychopharmacology

Volumn 22, Issue 1, 2007, Pages 57-61

  Eriksson, Tomas ^a  

^a LUND UNIVERSITY   (Sweden)

Author keywords

Anti androgens; Clinical trial; Gonadotropin releasing hormone; Obsessive compulsive disorder; Treatment; Triptorelin

Indexed keywords

ANTIANDROGEN; BUSPIRONE; CLOMIPRAMINE; CLONAZEPAM; FLUOXETINE; GONADORELIN DERIVATIVE; SERTRALINE; TRIPTORELIN;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; DISEASE SEVERITY; DRUG EFFICACY; HUMAN; MALE; OBSESSIVE COMPULSIVE DISORDER; PRIORITY JOURNAL; SEXUAL AROUSAL DISORDER; TREATMENT OUTCOME; VISUAL ANALOG SCALE;

ADULT; ANDROGEN ANTAGONISTS; ANTIPSYCHOTIC AGENTS; GONADOTROPIN-RELEASING HORMONE; HUMANS; LUTEINIZING HORMONE; MALE; MIDDLE AGED; OBSESSIVE-COMPULSIVE DISORDER; PSYCHIATRIC STATUS RATING SCALES; TIME FACTORS; TREATMENT OUTCOME; TRIPTORELIN;

EID: 33845652185     PISSN: 02681315     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.yic.0000224793.51900.cb     Document Type: Article

References (16)

1. American Psychiatric Association (1994). Diagnostic and statistical manual of mental disorders. 4th ed. Washington, District of Columbia: American Psychiatric Association.
2. Barr LC, Goodman WK, McDougle CJ, Delgado PL, Heninger GR, Charney DS, et al. (1994). Tryptophan depletion in patients with obsessive-compulsive disorder who respond to serotonin reuptake inhibitors. Arch Gen Psychiatry 51:309-317.
3. Birger M, Swartz M, Cohen D, Alesh Y, Grishpan C, Kotelr M (2003). Aggression: the testosterone-serotonin link. Isr Med Assoc J 5:653-658.
4. Casas M, Alvarez E, Duro P, Garcia-Ribera C, Udina C, Velat A, et al. (1986). Antiandrogenic treatment of obsessive-compulsive neurosis. Acta Psych Scand 73:221-222.
5. Eriksson T (2000). Antiandrogenic treatment for obsessive-compulsive disorder. Am J Psychiatry 157:483-483.
6. Fineberg NA, Roberts A, Montgomery SA, Cowen PJ (1997). Brain 5-HT function in obsessive-compulsive disorder. Prolactin responses to d-fenfluramine. Br J Psychiatry 171:280-282.
7. Giammanco M, Tabacchi G, Giammanco S, Di Majo D, La Guardia M (2005). Testosterone and aggressiveness. Med Sci Monit 11:RA136-RA145.
8. Goodman WK, Price LH, Rasmussen SA, Mazure C, Fleischmann RL, Hill CL, et al. (1989a). The Yale-Brown Obsessive Compulsive Scale (Y-BOCS), part I: development, use and reliability. Arch Gen Psychiatry 46:1006-1011.
9. Goodman WK, Price LH, Rasmussen SA, Mazure C, Delgado P, Heninger GR, et al. (1989b). The Yale-Brown Obsessive Compulsive Scale (Y-BOCS), part II: validity. Arch Gen Psychiatry 46:1012-1016.
10. Hull EM, Muschamp JW, Sato S (2004). Dopamine and serotonin: influences on male sexual behavior. Physiol Behav 83:291-307.
11. Jenike MA (1998). Drug treatment of obsessive-compulsive disorder. In: Jenike A, Baer L, Minichiello WE, editors. Obsessive-compulsive disorder, practical management. 3rd ed. St Louis, Missouri: Mosby Inc. pp. 469-532.
12. Peterson BS, Zhang H, Anderson GM, Leckman JF (1998). A double-blind, placebo-controlled, crossover trial of an antiandrogen in the treatment of Tourettés syndrome. J Clin Psychopharmacol 18:324-331.
13. Pinto A, Mancebo MC, Eisen JL, Pagano ME, Rasmussen SA (2006). The Brown longitudinal obsessive compulsive study: clinical features and symptoms of the sample at intake. J Clin Psychiatry 67:703-711.
14. Schröder FH (1999). Endocrine treatment of prostate cancer: recent developments and the future. Part 1: maximal androgen blockade, early vs delayed endocrine treatment and side-effects. BJU Int 83:161-170.
15. Skoog G, Skoog I (1999). A 40-year follow-up of patients with obsessive-compulsive disorder. Arch Gen Psychiatry 56:121-127.
16. Weiss M, Baerg E, Wisebord S, Temple J (1995). The influence of gonadal hormones on periodicity of obsessive-compulsive disorder. Can J Psychiatry 40:205-207.